MedTrace Logo

Circulating Tumor Cells Screen for Breast Cancer

NCT05633680 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2023-03-13

No results posted yet for this study

Summary

A prospective study was used to collect patients considering breast cancer admitted to our general surgery department from 2019-6 to 2023-8, to identify the case group (breast cancer) and the control group (non-breast cancer), to compare the differences in CTC in peripheral blood between the two groups, and to draw conclusions after statistical analysis.

Conditions

  • Breast Neoplasm
  • Neoplastic Cells, Circulating

Interventions

DIAGNOSTIC_TEST

Peripheral blood sampling for circulating tumor cells

Patients had 3-4 ml of venous blood drawn on day 1 after admission, ethylene diamine tetra acetic acid (EDTA) was used for anticoagulation, samples were stored at 4 ℃, and CTCs analysis was performed within 24 hours after collection. .FU/3 ml was used as the unit for CTC quantification.

Sponsors & Collaborators

  • Handan First Hospital

    lead OTHER

Principal Investigators

  • kunwu yan, Master · Handan First Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-20
Primary Completion
2023-04-20
Completion
2023-06-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633680 on ClinicalTrials.gov